We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Genetix Grp | GTX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 84.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 84.00 |
| Top Posts |
|---|
Posted at 25/8/2009 11:12 by investinggarden Hold recommendation from Growth Company Investor |
Posted at 17/1/2008 19:34 by simonbroughton Featured on the growth company investor website today. It's the first time I've looked at these since 2000/2001.It's good to see survivors from that era starting to make it at last. |
Posted at 01/3/2006 14:24 by scumdog Decent enough results. However, only 55% of profit before tax is from operations - the remainder is interest received on the £25m cash pile their holding.This company exhibits similar characteristics to Celsis (CEL) which also holds a significant amount of cash. Celsis does pays a (smallish) dividend whereas no mention of dividends in the Genetix statement today. The Celsis share price has traded within a narrow range for 18 months now. The biotech sector doesn't appear popular with investors at present and hasn't been for 2 or 3 years. |
Posted at 05/11/2003 13:45 by mad4it pfb5I seek not attention, I seek investors! Good to have some company. p.s. I don't understand my last two posts either! ;) |
Posted at 29/10/2003 13:30 by mad4it Anyone watching these ? I bought a few at 48p and 60p.This looks like a good potential recovery story to me. A profitable company, with Approx 29p in cash, supplying state of the art equipment to the biotech industry. Recent director purchase of 50k at 55p and it's good to see the options issued to the new COO at 51.5p are performance related. I remember when GTX floated, their products were considered second to none. We are seeing a lot of growth in the biotech areas where they are supplying products and their products are still seen as a must have by the big Pharma companies (see below). Worth a punt I reckon. Here's the most recent, relevant info: 29/07/03: LONDON (AFX) - Genetix Group PLC said sales fell to 4.9 mln stg from 6.3 mln stg in a continuing difficult trading environment. For the six months to June 30, pre-tax profit fell to 0.2 million from 1 mln stg in 2002. It said conditions were challenging throughout the first six months of 2003. Difficulties for the biotechnology sector in raising funds, cutbacks and delays in academic grants, and pressure on pharmaceutical companies to orientate their R&D towards late-stage products have put pressure on supplier companies such as Genetix, it said. But despite these "tough conditions", Genetix remains profitable overall and financially strong with 21.4 mln stg of cash in the bank and an innovative pipeline of new products to generate future revenue, it said. Looking ahead, it said it remains confident in the company's ability to increase its market share as well as the opportunities to enter new markets. But in view of the continuing uncertain trading environment, the company remain cautious about prospects for 2003, although it anticipates maintaining a strong cash position of over 20 mln stg throughout the year. "We are encouraged by recent signs of a return of investor confidence in the biotech sector on the back of promising clinical data and product approvals, which underline the long-term promise of the industry," it said. .................... RNS Number:5130O Genetix Group PLC 11 August 2003 Genetix launches the aliQuot liquid handler Pre-launch orders placed by two of the top three major pharmaceutical companies Boston, USA, 11 August 2003 - Genetix Group plc (LSE: GTX), the genomics and proteomics technology group, today announces the launch of the aliQuot, an automated solution for the low volume dispensing of reagents, chemicals, cells, beads, reaction mixes and other media, at the Drug Discovery Technology conference in Boston, USA. The aliQuot, a desktop machine, uses a proprietary fast pressure-timing dispense mechanism to fill a 1536-well plate with one microlitre in under 30 seconds. The level of accuracy (well-to-well CV of approximately 5%) is unsurpassed by any other instrument in its price bracket. The major markets for this product will be drug discovery, forensics, genetic screening, genomics research and high throughput screening. Low volume dispensing is economically beneficial to pharmaceutical companies when testing compounds with reagents which can cost thousands of dollars per millilitre. Using smaller volumes in these assays enables a greater number of tests to be carried out, or the same number of tests at less cost. Another feature of the aliQuot which reduces the cost of assays is a backfilling function which allows unused compound or reagent remaining in the dispensing pipes to be flushed back into the reservoir bottle for future use. Future developments are likely to include the simultaneous dispensing of up to eight reagents. Julian Burke PhD, Chief Scientific Officer of Genetix, commented: "The aliQuot makes small volume dispensing accessible to laboratories previously unable to conduct assays on this scale because of budget or space constraints, it also offers a more economical solution to those larger companies already conducting tests on this level. Building on skills acquired during the development of the Qfill2 liquid handler, Genetix is able to offer this small volume capability at excellent speed and accuracy to it customers. Multiple pre-launch orders have already been received by two of the three leading pharmaceutical companies." |
Posted at 06/12/2000 09:42 by joe soap Well, it's been fun. I see that I'm not the only "small" investor who got scared and ran with their profits after the 333K sell. The price stayed stable considering, and probably has further to go, but I guess my nerves are a little frazled at the moment. I concur with Meg...the price may be stalling, but I'm happy. As I said, it's all about keeping a happy balance between buys and sells, and 333K is not a happy balance. Unlike the Minmet threads (if that's what they can be called), it's been very informative. See you all at the next IPO. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
